HILDEN, Germany, GERMANTOWN,
Maryland and BRIDGEWATER, New
Jersey, August 21, 2017
/PRNewswire/ --
QIAGEN (NASDAQ: QGEN; Frankfurt Prime
Standard: QIA) and Clinical Genomics, a private company developing
evidence-based diagnostic tools for colorectal cancer, today
announced they have implemented the PAXgene® Blood
ccfDNA Tube* sample collection in Clinical Genomics' Colvera™
colorectal cancer ("CRC") recurrence assay. Colvera, an integrated
liquid biopsy solution, is designed to enable easy and accurate
monitoring for recurrence of colorectal cancer with a simple blood
test collected in a physician's office.
"The Colvera test represents a unique opportunity for
convenient, non-invasive monitoring of colorectal cancer patients
by detecting methylated circulating tumor DNA that may indicate
recurrence of a cancer. We are pleased to collaborate with Clinical
Genomics in expanding the range of benefits made possible through
liquid biopsies, which hold great promise for improving the lives
of patients in cancer and other fields of medicine," said
Thierry Bernard, Senior Vice
President and Head of QIAGEN's Molecular Diagnostics Business
Area.
"We are extremely pleased to use the highly automated
QIAsymphony PAXgene Blood ccfDNA collection and sample processing
workflow for collection and handling of Colvera samples. As a
long-term commercial and research partner of QIAGEN, we have a
great deal of confidence in this new solution," said Dr.
Lawrence LaPointe, CEO of Clinical
Genomics. "We are excited to roll out the PAXgene System as the
front-end solution to allow physicians to provide Colvera testing
to CRC patients as conveniently as possible. PAXgene allows a
simple blood collection at the physician's office, with no on-site
processing required, which is a great step forward from our
alternative sample collection methods."
Click here for the full press release
http://corporate.qiagen.com/newsroom/press-releases/2017/2017-08-21-PAXgene-Colvera
Contacts:
QIAGEN
Investor Relations
John Gilardi
+49-2103-291-1711
e-mail:ir@QIAGEN.com
Public Relations
Dr. Thomas Theuringer
+49-2103- 291-1826
e-mail: pr@QIAGEN.com
CLINICAL GENOMICS
Media
Patty Jenkins
+1-908-300-8673
e-mail:ir@clinicalgenomics.com
SOURCE QIAGEN N.V.